<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39204242</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-0817</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>31</Day></PubDate></JournalIssue><Title>Pathogens (Basel, Switzerland)</Title><ISOAbbreviation>Pathogens</ISOAbbreviation></Journal><ArticleTitle>Serological Biomarkers in Individuals with Interstitial Lung Disease after SARS-CoV-2 Infection and Association with Post-COVID-19 Symptoms.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">641</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pathogens13080641</ELocationID><Abstract><AbstractText>Patients with interstitial lung disease (ILD) represent a vulnerable population against an acute SARS-CoV-2 infection. It has been observed that up to 80% of patients with ILD can develop post-COVID-19 symptomatology one year after. This secondary analysis aimed to, 1, compare serological biomarkers before and after surpassing a SARS-CoV-2 infection in individuals with interstitial lung disease (ILD) and, 2, to compare serological biomarkers between ILD patients who develop and those who do not develop post-COVID-19 symptoms. Seventy-six patients with ILD (40.4% women, age: 69, SD: 10.5 years) who survived a SARS-CoV-2 infection participated. High-resolution computerized tomography (CT) of the lungs, two pulmonary function tests (forced vital capacity (FVC) and diffusion value of carbon monoxide (DLCO)) and fourteen serological biomarkers were collected before and after SARS-CoV-2 infection. Participants were asked for the presence of post-COVID-19 symptomatology a mean of twelve (SD: eight) months after infection. Sixty patients (79%) showed post-COVID-19 symptoms (mean: 3.5, SD 1.1), with fatigue (68.4%), dyspnea (31.5%), and concentration loss (27.6%) being the most prevalent. Creatine phosphokinase (CPK) was the only biomarker showing differences in our study. In fact, CPK levels were higher after the acute SARS-CoV-2 infection (mean difference: 41.0, 95%CI 10.1 to 71.8, <i>p</i> = 0.03) when compared to before the infection. Thus, CPK levels were also higher in ILD patients with post-COVID-19 fatigue (mean difference: 69.7, 95%CI 12.7 to 126.7, <i>p</i> = 0.015) or with post-COVID-19 dyspnea (mean difference: 34.8, 95%CI 5.2 to 64.4, <i>p</i> = 0.025) than those patients without these post-COVID-19 symptoms. No significant changes in CT or functional pulmonary tests were observed after COVID-19 in patients with ILD. In conclusion, patients with ILD exhibited an increase in CPK levels after SARS-CoV-2 infection, albeit no changes in other serological biomarkers were identified. Similarly, the presence of post-COVID-19 fatigue or dyspnea was also associated with higher CPK levels in ILD patients. Studies investigating long COVID mechanisms in vulnerable populations such as ILD are needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Par&#xe1;s-Bravo</LastName><ForeName>Paula</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-7745-3006</Identifier><AffiliationInfo><Affiliation>Departamento de Enfermer&#xed;a, Universidad de Cantabria, 39005 Santander, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Grupo de Investigaci&#xf3;n en Enfermer&#xed;a, Instituto de Investigaci&#xf3;n Sanitaria Valdecilla (IDIVAL), 39011 Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-de-Las-Pe&#xf1;as</LastName><ForeName>C&#xe9;sar</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3772-9690</Identifier><AffiliationInfo><Affiliation>Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos (URJC), 28922 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrer-Pargada</LastName><ForeName>Diego</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-9088-5946</Identifier><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario Marqu&#xe9;s de Valdecilla, 39008 Cantabria, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izquierdo-Cuervo</LastName><ForeName>Sheila</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario Marqu&#xe9;s de Valdecilla, 39008 Cantabria, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Cacho</LastName><ForeName>Luis M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Departamento de Enfermer&#xed;a, Universidad de Cantabria, 39005 Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cifri&#xe1;n-Mart&#xed;nez</LastName><ForeName>Jos&#xe9; M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-3682-0142</Identifier><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario Marqu&#xe9;s de Valdecilla, 39008 Cantabria, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Druet-Toquero</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario Marqu&#xe9;s de Valdecilla, 39008 Cantabria, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pellicer-Valero</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-0104-1029</Identifier><AffiliationInfo><Affiliation>Image Processing Laboratory (IPL), Universitat de Val&#xe8;ncia, Parc Cient&#xed;fic, Paterna, 46980 Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrero-Montes</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5732-8344</Identifier><AffiliationInfo><Affiliation>Departamento de Enfermer&#xed;a, Universidad de Cantabria, 39005 Santander, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Grupo de Investigaci&#xf3;n en Enfermer&#xed;a, Instituto de Investigaci&#xf3;n Sanitaria Valdecilla (IDIVAL), 39011 Santander, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pathogens</MedlineTA><NlmUniqueID>101596317</NlmUniqueID><ISSNLinking>2076-0817</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">interstitial lung disease</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-COVID-19</Keyword><Keyword MajorTopicYN="N">serological biomarker</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>29</Day><Hour>1</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39204242</ArticleId><ArticleId IdType="pmc">PMC11356895</ArticleId><ArticleId IdType="doi">10.3390/pathogens13080641</ArticleId><ArticleId IdType="pii">pathogens13080641</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>GBD 2019 Chronic Respiratory Diseases Collaborators Global burden of chronic respiratory diseases and risk factors, 1990&#x2013;2019: An update from the Global Burden of Disease Study 2019. eClinicalMedicine. 2023;59:101936. doi: 10.1016/j.eclinm.2023.101936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.101936</ArticleId><ArticleId IdType="pmc">PMC7614570</ArticleId><ArticleId IdType="pubmed">37229504</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura Y., Suda T. Idiopathic pulmonary fibrosis: Diagnosis and clinical manifestations. Clin. Med. Insights Circ. Respir. Pulm. Med. 2015;9:163&#x2013;171. doi: 10.4137/CCRPM.S39897.</Citation><ArticleIdList><ArticleId IdType="doi">10.4137/CCRPM.S39897</ArticleId><ArticleId IdType="pmc">PMC5013866</ArticleId><ArticleId IdType="pubmed">27625576</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaul B., Cottin V., Collard H.R., Valenzuela C. Variability in global prevalence of Interstitial Lung Disease. Front. Med. 2021;8:751181. doi: 10.3389/fmed.2021.751181.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.751181</ArticleId><ArticleId IdType="pmc">PMC8599270</ArticleId><ArticleId IdType="pubmed">34805219</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox I.A., Borchers Arriagada N., de Graaff B., Corte T.J., Glaspole I., Lartey S., Walters E.H., Palmer A.J. Health-related quality of life of patients with idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Eur. Respir. Rev. 2020;29:200154. doi: 10.1183/16000617.0154-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/16000617.0154-2020</ArticleId><ArticleId IdType="pmc">PMC9488638</ArticleId><ArticleId IdType="pubmed">33153990</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzouvelekis A., Karampitsakos T., Kourtidou S., Bouros E., Tzilas V., Katsaras M., Antonou C., Dassiou M., Bouros D. Impact of depression on patients with Idiopathic Pulmonary Fibrosis. Front. Med. 2020;7:29. doi: 10.3389/fmed.2020.00029.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.00029</ArticleId><ArticleId IdType="pmc">PMC7020231</ArticleId><ArticleId IdType="pubmed">32118014</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Coronavirus (COVID-19) Dashboard. 2023.  [(accessed on 1 June 2024)].  Available online:  https://covid19.who.int/</Citation></Reference><Reference><Citation>Huang H., Zhang M., Chen C., Zhang H., Wei Y., Tian J., Shang J., Deng Y., Du A., Dai H. Clinical characteristics of COVID-19 in patients with preexisting ILD: A retrospective study in a single center in Wuhan, China. J. Med. Virol. 2020;92:2742&#x2013;2750. doi: 10.1002/jmv.26174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26174</ArticleId><ArticleId IdType="pmc">PMC7322991</ArticleId><ArticleId IdType="pubmed">32533777</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao C., Shi Y., Chen R., Liu X., Huang H., Zhao Y., Xu K., Chen K., Wang M., Xu Z. Risk factors associated with COVID-19 pneumonia in Chinese patients with pre-existing interstitial lung disease during the SARS-CoV-2 pandemic. J. Med. Virol. 2023;95:e29098. doi: 10.1002/jmv.29098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.29098</ArticleId><ArticleId IdType="pubmed">37707416</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos Martins M., Serino M., Martins B., Carvalho I., Valente C., Barbosa M., Cascais-Costa C., Terras-Alexandre A., Melo N., Caetano-Mota P., et al. Evolution of fibrotic interstitial lung diseases (ILD) after COVID-19. Eur. Resp. J. 2022;60:4172.</Citation></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C. Long COVID: Current definition. Infection. 2022;50:285&#x2013;286. doi: 10.1007/s15010-021-01696-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01696-5</ArticleId><ArticleId IdType="pmc">PMC8438555</ArticleId><ArticleId IdType="pubmed">34519974</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V. WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2022;22:e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes L.D., Ingram J., Sculthorpe N.F. More Than 100 Persistent Symptoms of SARS-CoV-2 (Long COVID): A scoping review. Front. Med. 2021;8:750378. doi: 10.3389/fmed.2021.750378.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.750378</ArticleId><ArticleId IdType="pmc">PMC8591053</ArticleId><ArticleId IdType="pubmed">34790680</ArticleId></ArticleIdList></Reference><Reference><Citation>Tirelli U., Franzini M., Chirumbolo S. Post-COVID syndrome, the real matter of debate. J. Med. Virol. 2023;95:e28785. doi: 10.1002/jmv.28785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28785</ArticleId><ArticleId IdType="pubmed">37212308</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C., Notarte K.I., Macasaet R., Velasco J.V., Catahay J.A., Therese Ver A., Chung W., Valera-Calero J.A., Navarro-Santana M. Persistence of post-COVID symptoms in the general population two years after SARS-CoV-2 infection: A systematic review and meta-analysis. J. Infect. 2024;88:77&#x2013;88. doi: 10.1016/j.jinf.2023.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2023.12.004</ArticleId><ArticleId IdType="pubmed">38101521</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoniou K.M., Vasarmidi E., Russell A.M., Andrejak C., Crestani B., Delcroix M., Dinh-Xuan A.T., Poletti V., Sverzellati N., Vitacca M., et al. European Respiratory Society statement on long COVID follow-up. Eur. Respir. J. 2022;60:2102174. doi: 10.1183/13993003.02174-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02174-2021</ArticleId><ArticleId IdType="pmc">PMC9349784</ArticleId><ArticleId IdType="pubmed">35144991</ArticleId></ArticleIdList></Reference><Reference><Citation>Par&#xe1;s-Bravo P., Fern&#xe1;ndez-de-las-Pe&#xf1;as C., Ferrer-Pargada D., Izquierdo-Cuervo S., Herrero-Montes M. Prevalence of post-COVID symptoms one-year after SARS-CoV-2 infection in patients with interstitial lung disease. Eur. J. Intern. Med. 2024;123:161&#x2013;162. doi: 10.1016/j.ejim.2024.01.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2024.01.039</ArticleId><ArticleId IdType="pubmed">38326148</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji P., Zhu J., Zhong Z., Li H., Pang J., Li B., Zhang J. Association of elevated inflammatory markers and severe COVID-19: A meta-analysis. Medicine. 2020;99:e23315. doi: 10.1097/MD.0000000000023315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000023315</ArticleId><ArticleId IdType="pmc">PMC7676531</ArticleId><ArticleId IdType="pubmed">33217868</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L., Dyer A.H., Jones K., Dunne J., Mooney A., Gaffney F., O&#x2019;Connor L., Leavy D., O&#x2019;Brien K., Dowds J., et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS ONE. 2020;15:e0240784. doi: 10.1371/journal.pone.0240784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0240784</ArticleId><ArticleId IdType="pmc">PMC7652254</ArticleId><ArticleId IdType="pubmed">33166287</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C., Ryan-Murua P., Rodr&#xed;guez-Jim&#xe9;nez J., Palacios-Ce&#xf1;a M., Arendt-Nielsen L., Torres-Macho J. Serological biomarkers at hospital admission are not related to long-term post-COVID fatigue and dyspnea in COVID-19 survivors. Respiration. 2022;101:658&#x2013;665. doi: 10.1159/000524042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000524042</ArticleId><ArticleId IdType="pmc">PMC9148886</ArticleId><ArticleId IdType="pubmed">35381597</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C., Guijarro C., Velasco-Arribas M., Pellicer-Valero O., Torres-Macho J. Serological biomarkers at hospital admission and hospitalization treatments are not related to the development of post-COVID dyspnea. Eur. J. Intern. Med. 2024;119:132&#x2013;135. doi: 10.1016/j.ejim.2023.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2023.11.004</ArticleId><ArticleId IdType="pubmed">37945411</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C., Ryan-Murua P., de-la-Llave-Rinc&#xf3;n A., G&#xf3;mez-Mayordomo V., Arendt-Nielsen L., Torres-Macho J. Serological biomarkers of COVID-19 severity at hospital admission are not related to long-term post-COVID pain symptoms in hospitalized COVID-19 survivors. Pain. 2022;163:2112&#x2013;2117. doi: 10.1097/j.pain.0000000000002608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/j.pain.0000000000002608</ArticleId><ArticleId IdType="pmc">PMC9560903</ArticleId><ArticleId IdType="pubmed">35121694</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong S.J., Halim A., Halim M., Liu S., Aljeldah M., Al Shammari B.R., Alwarthan S., Alhajri M., Alawfi A., Alshengeti A., et al. Inflammatory and vascular biomarkers in post-COVID-19 syndrome: A systematic review and meta-analysis of over 20 biomarkers. Rev. Med. Virol. 2023;33:e2424. doi: 10.1002/rmv.2424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2424</ArticleId><ArticleId IdType="pubmed">36708022</ArticleId></ArticleIdList></Reference><Reference><Citation>Udeh R., Utrero-Rico A., Dolja-Gore X., Rahmati M., McEVoy M., Kenna T. Lactate dehydrogenase contribution to symptom persistence in long COVID: A pooled analysis. Rev. Med. Virol. 2023;33:e2477. doi: 10.1002/rmv.2477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2477</ArticleId><ArticleId IdType="pubmed">37706263</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E., Altman D.G., Egger M., Pocock S.J., Gotzsche P.C., Vandenbroucke J.P. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet. 2007;370:1453&#x2013;1457. doi: 10.1016/S0140-6736(07)61602-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)61602-X</ArticleId><ArticleId IdType="pubmed">18064739</ArticleId></ArticleIdList></Reference><Reference><Citation>Travis W.D., Costabel U., Hansell D.M., King T.E., Jr., Lynch D.A., Nicholson A.G., Ryerson C.J., Ryu J.H., Selman M., Wells A.U., et al. ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. Am. J. Respir. Crit. Care Med. 2013;188:733&#x2013;748. doi: 10.1164/rccm.201308-1483ST.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201308-1483ST</ArticleId><ArticleId IdType="pmc">PMC5803655</ArticleId><ArticleId IdType="pubmed">24032382</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijsenbeek M., Suzuki A., Maher T.M. Interstitial lung diseases. Lancet. 2022;400:769&#x2013;786. doi: 10.1016/S0140-6736(22)01052-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01052-2</ArticleId><ArticleId IdType="pubmed">35964592</ArticleId></ArticleIdList></Reference><Reference><Citation>Culver B.H., Graham B.L., Coates A.L., Wanger J., Berry C.E., Clarke P.K., Hallstrand T.S., Hankinson J.L., Kaminsky D.A., MacIntyre N.R., et al. ATS Committee on Proficiency Standards for Pulmonary Function Laboratories. Recommendations for a Standardized Pulmonary Function Report. An Official American Thoracic Society Technical Statement. Am. J. Respir. Crit. Care Med. 2017;196:1463&#x2013;1472. doi: 10.1164/rccm.201710-1981ST.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201710-1981ST</ArticleId><ArticleId IdType="pubmed">29192835</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen R.J., Guillen-Guio B., Croot E., Kraven L.M., Moss S., Stewart I., Jenkins R.G., Wain L.V. Genetic overlap between idiopathic pulmonary fibrosis and COVID-19. Eur. Respir. J. 2022;60:2103132. doi: 10.1183/13993003.03132-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.03132-2021</ArticleId><ArticleId IdType="pmc">PMC9130756</ArticleId><ArticleId IdType="pubmed">35595312</ArticleId></ArticleIdList></Reference><Reference><Citation>Kewalramani N., Heenan K.M., McKeegan D., Chaudhuri N. Post-COVID interstitial lung disease: The tip of the iceberg. Immunol. Allergy Clin. N. Am. 2023;43:389&#x2013;410. doi: 10.1016/j.iac.2023.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.iac.2023.01.004</ArticleId><ArticleId IdType="pmc">PMC9982726</ArticleId><ArticleId IdType="pubmed">37055095</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin L.B., Weinstock L.B., Molderings G.J. COVID-19 hyperinflammation and post-COVID-19 illness may be rooted in mast cell activation syndrome. Int. J. Infect. Dis. 2020;100:327&#x2013;332. doi: 10.1016/j.ijid.2020.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.09.016</ArticleId><ArticleId IdType="pmc">PMC7529115</ArticleId><ArticleId IdType="pubmed">32920235</ArticleId></ArticleIdList></Reference><Reference><Citation>So M., Kabata H., Fukunaga K., Takagi H., Kuno T. Radiological and functional lung sequelae of COVID-19: A systematic review and meta-analysis. BMC Pulm. Med. 2021;21:97. doi: 10.1186/s12890-021-01463-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12890-021-01463-0</ArticleId><ArticleId IdType="pmc">PMC7983097</ArticleId><ArticleId IdType="pubmed">33752639</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhalla S., Ramirez C., Ziad M., Almaguer A., Cruz A.C., Gonzalez L&#xf3;pez J.S., Emeaba N., Akinwale D., Hussaini N.N., Varon D.S., et al. Elevated creatine phosphokinase in patients with COVID-19. Chest. 2022;162:A861&#x2013;A862. doi: 10.1016/j.chest.2022.08.682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2022.08.682</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rosa A., Verrengia E.P., Merlo I., Rea F., Siciliano G., Corrao G., Prelle A. Muscle manifestations and CK levels in COVID infection: Results of a large cohort of patients inside a Pandemic COVID-19 Area. Acta Myol. 2021;40:1&#x2013;7. doi: 10.1016/j.jns.2021.119838.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2021.119838</ArticleId><ArticleId IdType="pmc">PMC8033429</ArticleId><ArticleId IdType="pubmed">33870093</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman S.A., Charmchi Z., Silver M., Jacoby N., Perk J., Anziska Y. Skeletal muscle manifestations and creatine kinase in COVID-19. Neurohospitalist. 2022;12:597&#x2013;606. doi: 10.1177/19418744221105961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/19418744221105961</ArticleId><ArticleId IdType="pmc">PMC9160579</ArticleId><ArticleId IdType="pubmed">36147765</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponti G., Maccaferri M., Ruini C., Tomasi A., Ozben T. Biomarkers associated with COVID-19 disease progression. Crit. Rev. Clin. Lab. Sci. 2020;57:389&#x2013;399. doi: 10.1080/10408363.2020.1770685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10408363.2020.1770685</ArticleId><ArticleId IdType="pmc">PMC7284147</ArticleId><ArticleId IdType="pubmed">32503382</ArticleId></ArticleIdList></Reference><Reference><Citation>Untersmayr E., Venter C., Smith P., Rohrhofer J., Ndwandwe C., Schwarze J., Shannon E., Sokolowska M., Sadlier C., O&#x2019;Mahony L. Immune mechanisms underpinning long COVID: Collegium Internationale Allergologicum Update 2024. Int. Arch. Allergy Immunol. 2024;185:489&#x2013;502. doi: 10.1159/000535736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000535736</ArticleId><ArticleId IdType="pubmed">38253027</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo D., Mei B., Wang P., Li X., Chen X., Wei G., Kuang F., Li B., Su S. Prevalence and risk factors for persistent symptoms after COVID-19: A systematic review and meta-analysis. Clin. Microbiol. Infect. 2024;30:328&#x2013;335. doi: 10.1016/j.cmi.2023.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2023.10.016</ArticleId><ArticleId IdType="pubmed">37866679</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>